Shots: Ionis to receive $35M upfront, $55M as future milestones and royalties on net sales. Biogen to get worldwide development and commercialization rights and will be responsible for cost of […]readmore
Tags : Amyotrophic Lateral Sclerosis (ALS)
Shots: The Notice of Compliance (NOC) authorization is based on the clinical trial assessing Radicava (edaravone), demonstrating its positive 1EP measured by using the ALSFRS-R Edaravone is a IV medication, […]readmore